Pipeline

Sorrento's R&D wa ni idojukọ lori imotuntun awakọ ni COVID-19, itọju alakan, iṣakoso irora ni kikun ati awọn aarun autoimmune

Awọn eto bọtini Ifarahan Preclinical Igbese I Igbese II Ipele III/Pivotal FDA Approval
Awọn eto COVID-19  

COVISTIX™ (aisan ayẹwo) Dekun Antijeni igbeyewo

*

Aṣẹ Lilo pajawiri (EUA) ni Mexico (COFEPRIS), Brazil (ANVISA), ati CE Ti samisi ni Yuroopu

COVIMARK™ (aisan ayẹwo) Dekun Antijeni igbeyewo

*

Ohun elo ti a fi silẹ ni AMẸRIKA ati Kanada fun Aṣẹ Lilo pajawiri (EUA)

VIREX (aisan ayẹwo) Ni Ile Aisan

60.2%*

EUA Enabling Studies in Q3 2022

COVISHIELD™ (itọju) Antibody Neutralizing (IV) ni Awọn Alaisan ati Awọn Alabojuto

20%*

FUJOVEE™ (Abivertinib) COVID-19 to lagbara ni Awọn alaisan ICU

82%*

Idanwo pataki ni isunmọtosi imukuro FDA

OQORY™ (COVI-MSC) ARDS nitori COVID-19 ni Awọn alaisan ICU

82%*

Idanwo pataki ni Ilu Brazil

Mpro Olugbeja (ògùn ẹnu) Alatako-ọlọjẹ

40%*

Omicron mRNA ajesara Ajesara

20%*

Awọn eto bọtini Ifarahan Preclinical Igbese I Igbese II Ipele III/Pivotal FDA Approval
ajẹsara  

FUJOVEE™ (Abivertinib) NSCLC

82%*

FUJOVEE™ (Abivertinib) B Cell Lymphomas

60.2%*

FUJOVEE™ (Abivertinib) Ibo ori

20%*

FUJOVEE™ (Abivertinib) lupus

20%*

FUJOVEE™ (Abivertinib) MS

20%*

FUJOVEE™ (Abivertinib) GvHD

20%*

PD-L1 (Socazolimab)* SCLC

82%*

* Ni Ajọṣepọ pẹlu Lee's Pharm ni Ilu China

PD-L1 (STI-3031)** obo akàn

82%*

** Ni AMẸRIKA ati ni ajọṣepọ pẹlu ImmuneOncia ni Koria

CD47 Awọn èèmọ to lagbara

40%*

CD38 DAR-T Ọpọlọ Myeloma

40%*

CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, ati esophageal

40%*

Seprehvec™ oncolytic kokoro Awọn èèmọ to lagbara; Awọn èèmọ CNS

40%*

BMA ADC Awọn èèmọ olomi

20%*

Bevacizumab-ADNAB™ Ọgbẹ ti ipilẹṣẹ

40%*

Ni ajọṣepọ pẹlu awọn Mayo Clinic

Bevacizumab-ADNAB™ Ovarian Cancer

40%*

Ni ajọṣepọ pẹlu awọn Mayo Clinic

Rituximab-ADNAB™ B-cell Lymphomas

40%*

Ni ajọṣepọ pẹlu awọn Mayo Clinic

Sofusa® egboogi-PD-1 Ẹjẹ T-Cell Lymphoma (CTCL), Melanoma

40%*

Awọn eto bọtini Ifarahan Preclinical Igbese I Igbese II Ipele III/Pivotal FDA Approval
irora  

ZTlido® 1.8%
Neuralgia Postherpetic - PHN

99.8%*

Gloperba®
Itoju ti Gout (Oral)

99.8%*

SEMEXA (SP-102) Lumbar Radicular/Irora Sciatica

82%*

SP-103 (Eto Ipilẹ Lidocaine 5.4%) Irora Pada irora

60.2%*

SP-104 (Idaduro Burst Iwọn Kekere Naltrexone) Fibromyalgia

20%*

RTX (resiniferatoxin)
Abẹrẹ epidural
Irora ti ko le fa ni Ilọsiwaju Akàn

60.3%*

Orphan yiyan

RTX (resiniferatoxin)
Ona-intra-articular
Iwontunwonsi si Irora Orunkun Okun

60.2%*

Awọn eto bọtini Ifarahan Preclinical Igbese I Igbese II Ipele III/Pivotal FDA Approval
Ifijiṣẹ Oògùn Lymphatic  

Sofusa® egboogi-TNF Aifọwọyi (RA)

40%*

Sofusa® egboogi-PD-1 Ẹjẹ T-Cell Lymphoma (CTCL), Melanoma

40%*

Sofusa® egboogi-CTLA-4 Melanoma

40%*

Ni ajọṣepọ pẹlu awọn Mayo Clinic
Awọn eto COVID-19
Awọn eto bọtini (Itọkasi) alakoso
COVISTIX™ (aisan ayẹwo) FDA EUA
COVIMARK™ (aisan ayẹwo) FDA EUA
VIREX (aisan ayẹwo) PH III
COVISHIELD™ (itọju) PH I
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
Mpro Inhibitor (ògùn ẹnu) Ph II
Omicron mRNA ajesara Preclinical
ajẹsara
Awọn eto bọtini (Itọkasi) alakoso
FUJOVEE™ (Abivertinib) Ph III
FUJOVEE™ (Abivertinib) Ph II
FUJOVEE™ (Abivertinib) Preclinical
FUJOVEE™ (Abivertinib) Preclinical
FUJOVEE™ (Abivertinib) Preclinical
FUJOVEE™ (Abivertinib) Preclinical
PD-L1 (Socazolimab)* Ph III
PD-L1 (STI-3031)** Ph III
CD47 (Awọn èèmọ to lagbara) Ph I
CD38 DAR-T (Ọpọ Myeloma) Ph I
CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, ati esophageal) Ph I
Seprehvec™ oncolytic kokoro (Awọn èèmọ to lagbara; Awọn èèmọ CNS) PH I
BMA ADC (Awọn èèmọ olomi) Preclinical
Bevacizumab-ADNAB™ (Akàn Endometrial) Ph I
Bevacizumab-ADNAB™ (Akàn Ovarian) Ph I
Rituximab-ADNAB™ (Lymphomas B-cell) Ph I
Sofusa® egboogi-PD-1 (T-Cell Lymphoma (CTCL), Melanoma) Ph I
irora
Awọn eto bọtini (Itọkasi) alakoso
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) FDA Approval
Gloperba® 1.8% Itoju ti Gout (Oral) FDA Approval
SEMEXA (SP-102) Ph III
SP-103 (Eto Ipilẹ Lidocaine 5.4%) Ph II
SP-104 (Idaduro Burst Iwọn Kekere Naltrexone) Preclinical
RTX (resiniferatoxin) Abẹrẹ epidural Ph II
RTX (resiniferatoxin) Ona-intra-articular Ph II
Ifijiṣẹ Lymphatic
Awọn eto bọtini (Itọkasi) Igbese II
Sofusa® egboogi-TNF (Autoimmune RA) Ph I
Sofusa® egboogi-PD-1 (T-Cell Lymphoma (CTCL), Melanoma) Ph I
Sofusa® egboogi-CTLA-4 (Melanoma) Ph I